Endocrine Journal
Our official Japanese journal "Naibunpigaku Zasshi" was first issued in 1925 and renamed as "Nihon Naibunpigaku-kai Zasshi" in 1927. In 1954 the first issue of English official journal "Endocrinologia Japonica" was published continuing to Volume 39 in 1992 and then renamed as the present "Endocrine Journal" from Volume 40 in 1993.
Read more
Published by The Japan Endocrine Society  
6,307 registered articles
(updated on February 07, 2023)
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
2.860
2021 Journal Impact Factor (JIF)
JOURNAL PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 70 (2023) Issue 1 Pages 69-76
Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation Read more
Editor's pick

To date, familial partial lipodystrophy (FPLD) has been known to consist of seven types, and FPLD type 3 is a rare autosomal dominant genetic disorder caused by mutations of peroxisome proliferator-activated receptor γ gene. In this issue, Dr. Iizaka and colleague report the first pedigree of FPLD 3 in Japanese exemplifying prolonged insulin resistant diabetes mellitus, liver steatosis and hypertriglyceridemia with a relatively low degree of BMI and percentage of body fat. For all endocrinologists, attention should be paid to avoid overlooking lipodystrophy syndromes.

Volume 69 (2022) Issue 11 Pages 1285-1293
Thyrotropin receptor antagonists and inverse agonists, and their potential application to thyroid diseases Read more
Editor's pick

Molecular research on agonists / antagonists / inverse agonists in a variety of G-protein coupled receptors (GPCRs) has long attracted robust attention of endocrinologists. In this issue, Dr. Nagayama and Dr. Nishihara contributes an encyclopedic, well-organized article on the update of antagonists / inverse agonists research around the thyrotropin receptor (TSHR), providing us with promising therapeutic potential for Graves’ hyperthyroidism, non-autoimmune hyperthyroidism, thyroid cancer and resistance to thyroid hormone.

Volume 69 (2022) Issue 10 Pages 1159-1172
Therapeutic role of mesenchymal stem cells (MSCs) in diabetic kidney disease (DKD) Read more
Editor's pick

It has long been recognized that uncontrolled high blood pressure, dysmetabolism of glucose and lipids, and sustained inflammation and fibrosis are involved in the pathophysiology and progression of diabetic kidney disease (DKD) in an extremely complexed manner. It is therefore exactly a herculean issue to accurately identify patients with higher risks than we would imagine for end-stage renal diseases (ESRDs). In the October issue, Dr. Xu Ning and colleague provide an attractive review article focusing on potentials of mesenchymal stem cells (MSCs) for the treatment of such an intractable medical condition.

Volume 69 (2022) Issue 9 Pages 1053-1060
Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells Read more
Editor's pick

Epigenome-based drugs such as inhibitors against DNA methyltransferases (DNMTs) and histone deacetylase (HDACs) have long been employed for the treatment of a variety of malignancy and pre-cancer status. In this issue, Dr. Rie Hagiwara and colleague provide a convincing data set of in vitro experiments demonstrating a selective HDAC6 inhibitor, tubastatin A substantially suppresses the growth of as well as the ACTH secretion from a murine corticotroph cell line, AtT-20. The present study may open a fresh avenue for brand-new therapeutics in humans on pituitary neuroendocrine tumors including Cushing’s disease.

Volume 69 (2022) Issue 8 Pages 881-896
Advances in understanding of phosphate homeostasis and related disorders Read more
Editor's pick

Science and clinics on phosphate homeostasis are no doubt an authentic, royal road to endocrinology. As most of readers of Endocrine Journal well recognize, basic scientists and endocrinologists in Japan have made a huge contribution to the molecular medicine on fibroblast growth factor 23 (FGF 23) in this academic field. To STATE-OF-THE-ART REVIEW IN ENDOCRINOLOGY in this issue, Dr. Michigami contributes an extensive, well-organized article on the recent research progress in phosphate homeostasis and related disorders with a particular emphasis on FGF 23, providing us with an invaluable perspective for cutting-edge area of bone-mineral endocrinology.

View all featured articles
View all articles in current issue
Most viewed articles (January 2023)
Share this page
Browse by volume and issue
feedback
Top